56 Pages Posted: 4 May 2011
Date Written: April 2011
This paper quantifies the relationship between market size and innovation in the pharmaceutical industry. We estimate the elasticity of innovation, as measured by the number of new chemical entities appearing on the market for a given disease class, to the potential market size represented by the willingness of sufferers of diseases in that class (and others acting on their behalf such as insurers and governments) to spend on their treatment during the patent lifetime. We find positive significant elasticities with a point estimate under our preferred specification of 25.2%. This suggests that at the mean market size an additional $1.8 billion is required in additional patent life revenue to induce the invention of one additional new chemical entity. An elasticity substantially and significantly below one-half is also a plausible implication of the hypothesis that innovation in pharmaceuticals is becoming more difficult and expensive over time, as costs of regulatory approval rise and as the industry runs out of "low hanging fruit."
Keywords: elasticity, innovation, market size, pharmaceuticals
JEL Classification: L65, O31, O34
Suggested Citation: Suggested Citation
de Mouzon, Oliver and Dubois, Pierre and Scott Morton, Fiona M. and Seabright, Paul, Market Size and Pharmaceutical Innovation (April 2011). CEPR Discussion Paper No. DP8367. Available at SSRN: https://ssrn.com/abstract=1830985
This is a CEPR Discussion Paper. CEPR charges a fee of $5.00 for this paper.Login using your CEPR Personal Profile
File name: DP8367.
If you wish to purchase the right to make copies of this paper for distribution to others, please select the quantity.